Current siRNA targets in atherosclerosis and aortic aneurysm.
Current siRNA targets in atherosclerosis and aortic aneurysm.
复制标题
DOI：
--
复制
发表时间：
2014-05
影响因子：
1.4
通讯作者：
Leena Pradhan-Nabzdyk;Chenyu Huang;F. Logerfo;C. Nabzdyk
中科院分区：
文献类型：
--
作者：
Leena Pradhan-Nabzdyk;Chenyu Huang;F. Logerfo;C. Nabzdyk
动脉粥样硬化（ATH）和主动脉瘤（AA）仍然是具有挑战性的慢性疾病，尽管在医学、介入性和外科治疗方面取得了进展，但它们仍具有很高的发病率和死亡率。RNA干扰是一种很有前途的技术，可以用来沉默与ATH和AA有关的基因。尽管在临床前和一些临床可行性研究中取得了积极的结果，但诸如靶标/序列验证、组织特异性、转染效率和减轻不必要的脱靶效应等挑战仍有待解决。在这篇综述中，讨论了siRNA传递的最新靶点和一些新的方法。由于研究对象过多，仅包括2010年至2014年间发表的研究。
Atherosclerosis (ATH) and aortic aneurysms (AA) remain challenging chronic diseases that confer high morbidity and mortality despite advances in medical, interventional, and surgical care. RNA interference represents a promising technology that may be utilized to silence genes contributing to ATH and AA. Despite positive results in preclinical and some clinical feasibility studies, challenges such as target/sequence validation, tissue specificity, transfection efficiency, and mitigation of unwanted off-target effects remain to be addressed. In this review the most current targets and some novel approaches in siRNA delivery are being discussed. Due to the plethora of investigated targets, only studies published between 2010 and 2014 were included.